Drug intelligence / Profile preview

E5324

Development stage: Discontinued
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral

Overview

E5324 is a **small molecule drug** that acts as an **inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT1)**. It is primarily investigated for its effects on **cardiovascular diseases**, particularly for its anti-atherosclerotic properties. E5324 was developed by **Eisai Co., Ltd.**

Other names: n-butyl-N′-[2-[3-(5-ethyl-4-phenyl-1H-imidazol-1-yl)propoxy]-6-methylphenyl]urea

Targets

ACAT1 (Acyl-coenzyme A:cholesterol O-acyltransferase 1)

Beyond the preview

Go deeper on E5324.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E5324.

Explore the full profile